Evidence map›Paper›PMID 27499535›Full record

ArticleMayo Clinic proceedings2016

Serum Potassium, Mortality, and Kidney Outcomes in the Atherosclerosis Risk in Communities Study.

Yan Chen, Alex R Chang, Mara A McAdams DeMarco, Lesley A Inker, Kunihiro Matsushita, Shoshana H Ballew, Josef Coresh, Morgan E Grams

Open access · greenAbstract read
In one paragraph

Article in Mayo Clinic proceedings, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. [Cardiac arrest under special circumstances].Notfall & rettungsmedizin · 2021
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Yan ChenDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Alex R ChangDepartment of Nephrology, Geisinger Medical Center, Danville, PA.
Mara A McAdams DeMarcoDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Division of Transplant Surgery, Department of Surgery, Johns Hopkins University, Baltimore, MD.
Lesley A InkerDepartment of Nephrology, Tufts Medical Center, Boston, MA.
Kunihiro MatsushitaDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Shoshana H BallewDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Josef CoreshDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Division of General Internal Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD.
Morgan E GramsDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Division of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, MD. Electronic address: mgrams2@jhmi.edu.
Johns Hopkins University · USGeisinger Medical Center · USJohns Hopkins Medicine · USTufts Medical Center · US

Funding

Chronic Kidney Disease Prognosis Consortium (CKD-PC)R01DK100446 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI JOSEF CORESH, Morgan Erika Grams · 2014 to 2026
$10.7M
Morbid Obesity, Bariatric Surgery, and Kidney FunctionK23DK106515 · NIDDK · GEISINGER CLINIC · PI CHANG, ALEXANDER R · 2015 to 2019
$890k
The comparative effectiveness of kidney transplantation in advanced CKDK08DK092287 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI GRAMS, MORGAN ERIKA · 2012 to 2016
$793k
Frailty and Adverse Health Outcomes of Aging in Older Adults with Kidney FailureK01AG043501 · NIA · JOHNS HOPKINS UNIVERSITY · PI MCADAMS DEMARCO, MARA A. · 2014 to 2018
$624k
CCSP-FIELD CENTERN01HC055020 · HC · JOHNS HOPKINS UNIVERSITY · PI NIETO, F JAVIER · 1985 to 2000
$334k
NHLBI NIH HHS HHSN268201100005CNHLBI NIH HHS HHSN268201100005GNHLBI NIH HHS HHSN268201100005INHLBI NIH HHS HHSN268201100006CNHLBI NIH HHS HHSN268201100007CNHLBI NIH HHS HHSN268201100007INHLBI NIH HHS HHSN268201100008CNHLBI NIH HHS HHSN268201100008INHLBI NIH HHS HHSN268201100009CNHLBI NIH HHS HHSN268201100009INHLBI NIH HHS HHSN268201100010CNHLBI NIH HHS HHSN268201100011CNHLBI NIH HHS HHSN268201100011INHLBI NIH HHS HHSN268201100012CNHLBI NIH HHS N01 HC055020NIA NIH HHS K01 AG043501NIDDK NIH HHS K08 DK092287NIDDK NIH HHS K23 DK106515NIDDK NIH HHS R01 DK100446
6 · The paper itself

Abstract

objectivesTo investigate the association between serum potassium, mortality, and kidney outcomes in the general population and whether potassium-altering medications modify these associations. PATIENTS AND

methodsWe studied 15,539 adults in the Atherosclerosis Risk in Communities Study. Cox proportional hazard regression was used to investigate the association of serum potassium at baseline (1987-1989), evaluated categorically (hypokalemia, <3.5 mmol/L; normokalemia, ≥3.5 and <5.5 mmol/L; hyperkalemia, ≥5.5 mmol/L) and continuously using linear spline terms (knots at 3.5 and 5.5 mmol/L), with mortality, sudden cardiac death, incident chronic kidney disease, and end-stage renal disease. The end date of follow-up for all outcomes was December 31, 2012. We also evaluated whether classes of potassium-altering medications modified the association between serum potassium and adverse outcomes.

resultsOverall, 413 (2.7%) of the participants had hypokalemia and 321 (2.1%) had hyperkalemia. In a fully adjusted model, hyperkalemia was significantly associated with mortality (hazard ratio, 1.24; 95% CI, 1.04-1.49) but not sudden cardiac death, chronic kidney disease, or end-stage renal disease. Hypokalemia as a categorical variable was not associated with any outcome; however, associations of hypokalemia with all-cause mortality and kidney outcomes were observed among those who were not taking potassium-wasting diuretics (all P for interaction, <.001).

conclusionsHigher values of serum potassium were associated with a higher risk of mortality in the general population. Lower levels of potassium were associated with adverse kidney outcomes and mortality among participants not taking potassium-wasting diuretics.

Indexed as

AdultAgedDeath, Sudden, CardiacDiuretics, Potassium SparingGlomerular Filtration RateHumansHyperkalemiaHypokalemiaKidney Failure, ChronicMiddle AgedPotassiumProspective StudiesRenal Insufficiency, ChronicSodium Chloride Symporter InhibitorsUnited StatesDiuretics, Potassium SparingPotassiumSodium Chloride Symporter Inhibitors

Identifiers

PMID27499535
PMCPMC5531173
OpenAlexW2478710917

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.